A federal judge blocked the Federal Trade Commission (FTC) from investigating the Endocrine Society and World Professional Association for Transgender Health, which support gender-affirming care in minors. (Reuters via Yahoo! News)
Sanofi reportedly wants to pull its FDA priority voucher application for teplizumab (Tzield) after the agency’s top regulator overruled a staff recommendation to expand its use in type 1 diabetes. (Fierce Pharma)
Despite widespread reports of patients being unable to fill prescriptions, the FDA maintains there is no official shortage of estrogen patches. (NBC News)
Tirzepatide (Mounjaro) was associated with greater kidney protection compared with dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, an exploratory analysis of the SURPASS-CVOT trial found. (Lancet Diabetes & Endocrinology)
Experts are raising concerns about forever chemicals and phthalates in the U.S. infant formula supply after reviewing FDA data. (The Guardian)
Serum sample analysis of elite female track and field athletes found a higher prevalence of XY disorders of sex development compared to the general population. (Journal of Clinical Endocrinology & Metabolism)
Amazon Pharmacy will offer same-day delivery or kiosk pick-up for oral semaglutide (Ozempic) for type 2 diabetes. (Fierce Healthcare)
The New York Times reported a cultural shift in how modern television portrays menopause.
European regulators greenlit the first clinical trial for a beta cell-targeted GLP-1 gene therapy for type 2 diabetes, Fractyl Health announced.
Patients who underwent bariatric surgery showed gut microbiome alterations linked to type 2 diabetes remission, a subanalysis of a randomized trial found. (Nature Metabolism)
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/121228
Author :
Publish date : 2026-05-12 19:01:00
Copyright for syndicated content belongs to the linked Source.
